The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

OBJECTIVE: To evaluate radiographic progression in patients with ankylosing spondylitis (AS) receiving two different doses of the tumour necrosis factor antagonist golimumab. METHODS: 356 patients with AS were randomly assigned to placebo, or golimumab 50 mg or 100 mg every 4 weeks (wks). At wk16, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Jürgen, Baraliakos, Xenofon, Hermann, Kay-Geert A, Deodhar, Atul, van der Heijde, Désirée, Inman, Robert, Beutler, Anna, Zhou, Yiying, Xu, Stephen, Hsu, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033110/
https://www.ncbi.nlm.nih.gov/pubmed/23644549
http://dx.doi.org/10.1136/annrheumdis-2012-203075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033110/
https://www.ncbi.nlm.nih.gov/pubmed/23644549
http://dx.doi.org/10.1136/annrheumdis-2012-203075

Ejemplares similares